Nausea (most common, typically dose-dependent and transient) Diarrhea or constipation during dose escalation Vomiting, especially when starting or increasing dose Reduced appetite and early satiety Injection site reactions (redness, bruising) Fatigue, particularly in early weeks Rare: Pancreatitis discontinue immediately with severe abdominal pain Rare: Thyroid C-cell effects (contraindicated with MEN2 or thyroid cancer history) AOD-9604 is a modified C-terminal fragment (residues 176191, Tyr-hGH177-191) of human growth hormone, studied for lipolytic and anti-obesity properties
Check your blood sugar If you use tirzepatide for diabetes management, check your blood glucose more frequently for the next few days
WADA does not explicitly list AOD-9604 as a prohibited substance, but as an hGH analogue it falls under category S2
At DermaGlow, we prioritize safety, precision, and optimal results
Six trials totaling roughly 900 participants are summarized in Stier et al
At Coastal Glo, we approach every treatment with compassion, listening to your needs and making sure you feel cared for from the moment you walk in
